Show simple item record

dc.contributor.authorChang, Anne B
dc.contributor.authorFortescue, Rebecca
dc.contributor.authorGrimwood, Keith
dc.contributor.authorAlexopoulou, Efthymia
dc.contributor.authorBell, Leanne
dc.contributor.authorBoyd, Jeanette
dc.contributor.authorBush, Andrew
dc.contributor.authorChalmers, James D
dc.contributor.authorHill, Adam T
dc.contributor.authorKaradag, Bulent
dc.contributor.authorMidulla, Fabio
dc.contributor.authorMcCallum, Gabrielle B
dc.contributor.authorPowell, Zena
dc.contributor.authorSnijders, Deborah
dc.contributor.authoret al.
dc.description.abstractThere is increasing awareness of bronchiectasis in children and adolescents, a chronic pulmonary disorder associated with poor quality-of-life for the child/adolescent and their parents, recurrent exacerbations and costs to the family and health systems. Optimal treatment improves clinical outcomes. Several national guidelines exist, but there are no international guidelines.The European Respiratory Society (ERS) Task Force for the management of paediatric bronchiectasis sought to identify evidence-based management (investigation and treatment) strategies. It used the ERS standardised process that included a systematic review of the literature and application of the GRADE approach to define the quality of the evidence and level of recommendations.A multidisciplinary team of specialists in paediatric and adult respiratory medicine, infectious disease, physiotherapy, primary care, nursing, radiology, immunology, methodology, patient advocacy and parents of children/adolescents with bronchiectasis considered the most relevant clinical questions (for both clinicians and patients) related to managing paediatric bronchiectasis. Fourteen key clinical questions (7 "Patient, Intervention, Comparison, Outcome" [PICO] and 7 narrative) were generated. The outcomes for each PICO were decided by voting by the panel and parent advisory group.This guideline addresses the definition, diagnostic approach and antibiotic treatment of exacerbations, pathogen eradication, long-term antibiotic therapy, asthma-type therapies (inhaled corticosteroids, bronchodilators), mucoactive drugs, airway clearance, investigation of underlying causes of bronchiectasis, disease monitoring, factors to consider before surgical treatment and the reversibility and prevention of bronchiectasis in children/adolescents. Benchmarking quality of care for children/adolescents with bronchiectasis to improve clinical outcomes and evidence gaps for future research could be based on these recommendations.en_US
dc.publisherEuropean Respiratory Society (ERS)en_US
dc.relation.ispartofjournalEuropean Respiratory Journalen_US
dc.subject.fieldofresearchPublic Health and Health Servicesen_US
dc.subject.fieldofresearchMedical and Health Sciencesen_US
dc.titleTask Force report: European Respiratory Society guidelines for the management of children and adolescents with bronchiectasisen_US
dc.typeJournal articleen_US
dc.type.descriptionC1 - Articlesen_US
dcterms.bibliographicCitationChang, AB; Fortescue, R; Grimwood, K; Alexopoulou, E; Bell, L; Boyd, J; Bush, A; Chalmers, JD; Hill, AT; Karadag, B; Midulla, F; McCallum, GB; Powell, Z; Snijders, D; et al., Task Force report: European Respiratory Society guidelines for the management of children and adolescents with bronchiectasis, European Respiratory Journal, 2021, pp. 2002990en_US
gro.description.notepublicThis publication has been entered as an advanced online version in Griffith Research Online.en_US
gro.hasfulltextNo Full Text
gro.griffith.authorGrimwood, Keith

Files in this item


There are no files associated with this item.

This item appears in the following Collection(s)

  • Journal articles
    Contains articles published by Griffith authors in scholarly journals.

Show simple item record